Evidence map›Paper›PMID 38538929›Full record

ArticleActa neurochirurgica2024

Molecular insights and the role of 18F-FDG-PET/CT in the diagnosis of spinal gliomas.

Yoshitaka Nagashima, Yusuke Nishimura, Kaoru Eguchi, Junya Yamaguchi, Shoichi Haimoto, Fumiharu Ohka, Kazuya Motomura, Takashi Abe, Mamoru Matsuo, Eisuke Tsukamoto and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neurochirurgica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Yoshitaka NagashimaDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8560, Japan.
Yusuke NishimuraDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8560, Japan. yusuken0411@med.nagoya-u.ac.jp.ORCID 0000-0001-9689-0586
Kaoru EguchiDepartment of Neurosurgery, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Junya YamaguchiDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8560, Japan.
Shoichi HaimotoDepartment of Neurosurgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Fumiharu OhkaDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8560, Japan.
Kazuya MotomuraDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8560, Japan.
Takashi AbeDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8560, Japan.
Mamoru MatsuoDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8560, Japan.
Eisuke TsukamotoDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8560, Japan.
Masahito HaraDepartment of Neurosurgery, Aichi Medical University, Nagakute, Japan.
Ryuta SaitoDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8560, Japan.
Nagoya University · JPAichi Cancer Center · JPAichi Medical University · JPNational Hospital Organization · JP

Funding

Japan Society for the Promotion of Science, Grant-in-Aid for Early-Career Scientists 20K17962
6 · The paper itself

Abstract

backgroundIn recent years, molecular findings on spinal gliomas have become increasingly important. This study aimed to investigate the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in the diagnosis of spinal glioma.

methodsThis study included patients diagnosed with spinal cord glioma who underwent 18F-FDG-PET examination at the Department of Neurosurgery, Nagoya University Hospital between January 2016 and November 2023. The gliomas were divided into two groups, high-grade and low-grade, based on pathological and molecular studies. The maximum standardized uptake values (SUVmax) of the tumors were quantified and subsequently represented using receiver operating characteristic (ROC) curves.

resultsEighteen participants were included in this study. Of the participants, seven had high-grade glioma with an SUVmax of 6.76 ± 0.72, and eleven had low-grade glioma with an SUVmax of 4.02 ± 1.78, and a statistically significant difference between the two groups. The ROC curve delineated an SUVmax cutoff value of 5.650, with an area under the curve (AUC) of approximately 0.909. Based on the cutoff value, the results of the diagnostic performance rendered a sensitivity and negative predictive value of 1.0, whereas the specificity and positive predictive value were 0.909 and 0.875, respectively.

conclusionsThe present study shows that 18F-FDG-PET exhibits a markedly sensitive and negative predictive value in the assessment of spinal gliomas. Additionally, these findings have potential implications for the qualitative assessment of spinal gliomas using 18F-FDG-PET/CT. This imaging modality may be useful for making timely treatment decisions in situations where a detailed diagnosis by molecular analysis is not possible.

Indexed as

Fluorodeoxyglucose F18GliomaHumansPositron-Emission TomographyPositron Emission Tomography Computed TomographyRadiopharmaceuticalsRetrospective StudiesFluorodeoxyglucose F18RadiopharmaceuticalsAstrocytomaDiffuse midline gliomaEpendymomaPositron emission tomography/computed tomographySpinal intramedullary tumors

Identifiers

PMID38538929
OpenAlexW4393234788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.